Androgen regulated prostate specific nucleic acids
AssigneeInstitute for Systems Biology
InventorBiaoyang Lin
Life of this patent
Estimating the term…
Abstract
The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided.
Claims71
A substantially pure ARP1 nucleic acid molecule, comprising substantially the nucleotide sequence shown as SEQ ID NO:
- 1.
A substantially pure ARP1 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 722 to 1026 of SEQ ID NO:
- 1.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP1 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 1;
- (b) determining a test expression level of ARP1 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP1 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP1 regulatory agent.
A substantially pure ARP2 nucleic acid molecule, comprising substantially the nucleotide sequence shown as SEQ ID NO:
- 2.
A substantially pure ARP2 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1128 to 4509 of SEQ ID NO:
- 2.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP2 nucleic acid molecule comprising at least 10 contiguous nucleotides of nucleotides 1128 to 4509 of SEQ ID NO:
- 2;
- (b) determining a test expression level of ARP2 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP2 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP2 regulatory agent.
A substantially pure ARP3 nucleic acid molecule, comprising a nucleic acid sequence encoding an ARP3 polypeptide having at least 45% amino acid identity with SEQ ID NO:
- 5.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP3 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 4;
- (b) determining a test expression level of ARP3 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP3 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP3 polypeptide, comprising an amino acid sequence having at least 45% amino acid identity with SEQ ID NO:
- 5.
A substantially pure ARP3 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:
- 5.
A binding agent, comprising a molecule that selectively binds an ARP3 polypeptide having at least 45% amino acid identity with SEQ ID NO:
- 5.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP3 regulatory agent.
A substantially pure ARP4 nucleic acid molecule, comprising a nucleic acid sequence encoding an ARP4 polypeptide having at least 50% amino acid identity with SEQ ID NO:
- 7.
A substantially pure ARP4 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 821 to 1940 of SEQ ID NO:
- 6.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP4 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 6;
- (b) determining a test expression level of ARP4 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP4 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP4 polypeptide, comprising an amino acid sequence having at least 50% amino acid identity with SEQ ID NO:
- 7.
A substantially pure ARP4 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:
- 7.
A binding agent, comprising a molecule that selectively binds an ARP4 polypeptide having at least 50% amino acid identity with SEQ ID NO:
- 7.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP4 regulatory agent.
A substantially pure ARP5 nucleic acid molecule, comprising a nucleic acid sequence encoding an ARP5 polypeptide having at least 40% amino acid identity with SEQ ID NO:
- 9.
The substantially pure ARP5 nucleic acid molecule of claim 56, comprising the nucleotide sequence shown as SEQ ID NO:
- 8.
A substantially pure ARP5 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 565 to 1276 of SEQ ID NO:
- 8.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP5 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 8;
- (b) determining a test expression level of ARP5 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP5 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP5 polypeptide, comprising substantially an amino acid sequence having at least 40% amino acid identity with SEQ ID NO:
- 9.
A substantially pure ARP5 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:
- 9.
A binding agent, comprising a molecule that selectively binds an ARP5 polypeptide having at least 40% amino acid identity with SEQ ID NO:
- 9.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP5 regulatory agent.
Dependencies are inferred from the claim text.